Patient Guide

Guide to Autoimmune Blood Tests

Autoimmune diseases are diagnosed with a panel of specific blood tests. Each test targets different antibodies. This guide explains which test detects which disease.2

Written by Suman Konda, Clinical Pharmacist · Based on peer-reviewed sources · Editorial policy · Not medical advice

Last reviewed and updated: · How we check our content

Quick answer

Autoimmune blood testing starts with ANA as the screening test, then follows a stepwise cascade of specific antibodies (anti-dsDNA, anti-CCP, ANCA and others) plus complement levels to pin down the disease. The core takeaway: a positive ANA alone does not diagnose autoimmune disease, and results must be read alongside symptoms and specialist review.

Autoimmune antibody tests at a glance

Autoimmune testing is ordered as a stepwise cascade, not a single panel. This table reorganises the tests covered in this guide by their role: screening first, specific confirmation next, activity markers alongside.

TestWhat a positive result points toRole in the workup
ANA (antinuclear antibody)Lupus, Sjögren’s, scleroderma and othersScreening — a positive result triggers the cascade
Anti-dsDNALupus (highly specific)Confirmation; levels track disease activity and renal flares
Anti-SmLupus (near-diagnostic when positive)Confirmation
Anti-Ro (SSA) / Anti-La (SSB)Sjögren’s syndrome; neonatal lupusConfirmation
Anti-Scl-70 (anti-topoisomerase)Diffuse systemic sclerosisConfirmation
Anti-centromereLimited systemic sclerosis (CREST)Confirmation
Anti-Jo-1Inflammatory myopathy (antisynthetase syndrome)Confirmation
Rheumatoid factor (RF)Rheumatoid arthritisScreening — less specific than anti-CCP
Anti-CCPRheumatoid arthritis (highly specific)Confirmation
ANCA (PR3 / MPO)Vasculitis (GPA, MPA)Investigation of suspected vasculitis
Complement C3 & C4Low levels signal active lupusActivity marker, tracked over time
CRP / ESRInflammation from any causeActivity marker, not disease-specific

No single antibody on this list diagnoses disease on its own — results are always read together with symptoms and examination.

Autoimmune blood tests and what they detect

Advertisement
TestPrimary diseaseSensitivity
ANA (antinuclear antibody)Lupus (SLE): screening test95% in SLE
Anti-dsDNALupus: specific, tracks disease activity70% in SLE
Anti-SmLupus: highly specific25% in SLE
Anti-Ro (SSA) / Anti-La (SSB)Sjögren's syndrome, neonatal lupus~75% in Sjögren's
Rheumatoid Factor (RF)Rheumatoid arthritis (RA)70–80% in RA
Anti-CCPRheumatoid arthritis: more specific than RF370–80% in RA, >99% specific
Anti-Scl-70 (anti-topoisomerase)Diffuse cutaneous scleroderma~40% in scleroderma
Anti-centromereLimited scleroderma (CREST syndrome)~80% in limited scleroderma
ANCA (PR3 / MPO)Vasculitis (GPA, MPA)~90% in active GPA
Anti-Jo-1Polymyositis / dermatomyositis~25% in IIM
Complement C3 & C4Low in lupus flares, hereditary complement deficiencyTrack disease activity
Key points
  • ANA is the screening test; a positive result triggers a stepwise antibody cascade.
  • Low C3 and C4 complement plus high anti-dsDNA signals active lupus.
  • A positive ANA alone does not diagnose disease; many healthy people test positive at low titre.
  • Anti-CCP is specific for rheumatoid arthritis; ANCA points to vasculitis.

The ANA cascade, how autoimmune testing is done stepwise

Antinuclear antibody (ANA) testing is the entry point for investigating suspected autoimmune disease. However, a positive ANA alone does not diagnose autoimmune disease, it is a screening test that triggers a cascade of more specific tests:

  1. ANA by immunofluorescence: Detects antibodies that bind to nuclear material. Reported as a titre (e.g., 1:80, 1:160, 1:320) and pattern (homogeneous, speckled, nucleolar, centromere). Positive at 1:160 or above is clinically significant; 1:80 is found in up to 15% of healthy adults and 30% of healthy older adults, the threshold matters enormously.1
  2. If ANA positive, specific extractable nuclear antigen (ENA) antibodies are measured:
    • Anti-dsDNA: Highly specific for systemic lupus erythematosus (SLE); levels correlate with disease activity and can predict renal flares.
    • Anti-Sm: Also highly specific for SLE; less sensitive but when positive is near-diagnostic.
    • Anti-Ro (SS-A) and anti-La (SS-B): Sjögren's syndrome; also found in neonatal lupus (anti-Ro crosses the placenta and can cause neonatal heart block).
    • Anti-Scl-70 (anti-topoisomerase I): Systemic sclerosis (diffuse pattern).
    • Anti-centromere: Limited systemic sclerosis (CREST syndrome).
    • Anti-Jo-1: Antisynthetase syndrome (inflammatory myopathy + interstitial lung disease).

The choice of which ENAs to test depends on the clinical presentation, ordering the full ENA panel in every ANA-positive patient leads to false-positive results and unnecessary investigation.

Complement proteins, active disease markers in lupus

Complement C3 and C4 are consumed when the immune system activates the complement cascade, as happens in active SLE, especially lupus nephritis. Low C3/C4 alongside raised anti-dsDNA indicates active lupus flare with immune complex deposition. Serial complement measurement is used to monitor treatment response in lupus nephritis, rising C3/C4 correlates with renal improvement. Complement is normal in the autoimmune conditions that are not complement-consuming (Sjögren's, most inflammatory myopathy).

ANCA testing, vasculitis investigation

Anti-neutrophil cytoplasmic antibodies (ANCA) are separate from ANA and are used to investigate systemic vasculitis:

  • PR3-ANCA (c-ANCA pattern): Associated with granulomatosis with polyangiitis (GPA, formerly Wegener's), presenting with upper respiratory (nosebleeds, saddle-nose deformity), pulmonary (haemoptysis, cavitating nodules), and renal (rapidly progressive glomerulonephritis) involvement.
  • MPO-ANCA (p-ANCA pattern): Associated with microscopic polyangiitis and eosinophilic GPA (Churg-Strauss), asthma, sinusitis, eosinophilia, mononeuritis multiplex, and renal disease.

ANCA-associated vasculitis is a medical emergency, untreated, it causes irreversible kidney failure within weeks to months. Early diagnosis and treatment with cyclophosphamide or rituclimab plus steroids is life-saving.

Questions to ask your rheumatologist

  • Which specific antibodies are positive in my case?
  • Do my antibody patterns point to one diagnosis?
  • Is my complement low: indicating active lupus?
  • Do I need further organ-specific investigations (kidney biopsy, lung function)?

Autoimmune testing myths vs facts

MYTH A positive ANA means you have lupus.

Fact: ANA is a screening test, and low-titre positivity is common in healthy people. A positive ANA triggers the specific antibody cascade — it is the start of the investigation, not the diagnosis.

MYTH Normal autoimmune blood tests rule out autoimmune disease.

Fact: Not entirely. Some autoimmune conditions can be present with normal or borderline results, so tests are always interpreted alongside symptoms and examination rather than in isolation.

MYTH Testing for every antibody at once is the thorough option.

Fact: Ordering the full ENA panel in every ANA-positive patient produces false positives and unnecessary investigation. The choice of which antibodies to test depends on the clinical presentation.

MYTH A higher antibody level always means worse disease.

Fact: Some antibodies are diagnostic markers, not activity gauges. Anti-dsDNA levels do track lupus activity, but for most antibodies the trend and the clinical picture matter more than any single number — discuss yours with your rheumatologist.

What matters most in autoimmune testing

  • The cascade beats any single antibody: ANA first, then the specific tests your presentation calls for.
  • Low-titre ANA alone means little: many healthy people test positive at low titre.
  • Complement plus anti-dsDNA: low C3/C4 alongside raised anti-dsDNA is the reliable signal of active lupus.
  • Ask which antibodies are positive in your case and what pattern they point to — that is the question that moves the diagnosis forward.

Practical notes

Autoimmune antibody tests such as ANA usually need no fasting. Tell your doctor about every medicine and supplement you take, since some drugs can influence autoantibody results, and mention any recent infection — infections can cause temporary positive results that confuse the picture.

Bring a dated list of your symptoms and any family history of autoimmune disease; patterns over time help the rheumatologist more than a single test. Ask what a positive result would trigger next — usually a stepwise cascade of more specific antibody tests, not an immediate diagnosis.

Read results in context: ANA can be positive in healthy people, especially at low levels, and a single positive result rarely equals a disease. Rheumatologists interpret the antibody pattern together with your symptoms, examination and inflammatory markers, not the number alone.

Once a diagnosis is made, follow the specialist’s review schedule rather than repeating antibody tests on your own — monitoring usually shifts to markers of disease activity. If new symptoms appear between appointments, report them promptly instead of ordering repeat tests yourself.

In India

In India, an ANA test by immunofluorescence typically costs ₹1,200–₹2,500, and more specific antibody panels cost more, though prices vary by city and lab. Because testing is stepwise, ask what each stage costs before agreeing to the full cascade.

Choose an NABL-accredited laboratory — autoantibody testing is method-sensitive, so quality matters more than price. Home sample collection is available in major cities, and the reference range printed on your own report is the one that counts.

Frequently Asked Questions

What is the ANA test used for?
The antinuclear antibody (ANA) test is a screening test for autoimmune conditions such as lupus. A positive result needs interpretation, as some healthy people test positive and further specific antibody tests are often needed.
Do normal autoimmune blood tests rule out disease?
Not entirely: some autoimmune conditions can be present with normal or borderline results, so tests are always interpreted alongside symptoms and examination rather than in isolation.
Why are inflammatory markers checked too?
CRP and ESR measure inflammation and help gauge disease activity in autoimmune conditions, complementing the specific antibody tests used to reach a diagnosis.
How long do autoimmune blood test results take?
Simple tests such as CRP, ESR and complement levels are often reported the same or next day. Antibody panels — the ANA cascade, ENA panel and ANCA — are often sent to reference laboratories and can take several days to a couple of weeks. Ask the lab when you book.
My ANA came back positive — does that mean I have lupus?
No. ANA is positive in many healthy people and in several other conditions, so it is a clue, not a diagnosis. A rheumatologist will weigh the result alongside your symptoms and order confirmatory tests before naming any condition.
My doctor ordered ‘the ANA cascade’ — what does that actually mean?
It means stepwise testing: a screening ANA first, then more specific antibody tests only if the screen is positive or the clinical picture warrants it. This avoids paying for — and worrying about — tests you don’t need.
Should I stop my medicines before the blood draw?
Usually you take them as normal, but your doctor needs the full list because some medicines affect autoantibody tests. Never stop a prescribed medicine for a test without your doctor’s explicit instruction.
How often will these tests be repeated once I’m diagnosed?
It depends on the condition and the treatment — some markers are checked at every review, others rarely. Your specialist sets the schedule, so follow it rather than arranging repeats yourself.

References

Sources cited on this page. PubMed links open the original abstract.

  1. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum. 1997;40(9):1601–1611. PMID 9324014 · doi:10.1002/art.1780400909
  2. Bossuyt X, De Langhe E, Borghi MO, Meroni PL. "Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases." Nat Rev Rheumatol. 2020;16(12):715–726. PMID 33154583 · doi:10.1038/s41584-020-00522-w
  3. Rönnelid J, Hansson M, Mathsson-Alm L, et al. "Autoantibodies in Rheumatoid Arthritis – Laboratory and Clinical Perspectives." Front Immunol. 2021;12:685312. PMID 34054878 · doi:10.3389/fimmu.2021.685312
Medical Disclaimer: For educational purposes only. Always consult a qualified healthcare professional for diagnosis and treatment.
Written and medically reviewed by Suman Konda, Clinical Pharmacist · Sources linked to PubMed · Not medical advice: see our disclaimer